Nomination Date: 11/13/2003
Nominator: Private Individual
Rationale: The rapidly growing use of testosterone therapy has outpaced the meager scientific evidence about its benefits and risks. Testosterone therapy has been approved by the FDA only for treating a narrow group of clinical conditions marked by very low testosterone levels, yet doctors have been prescribing it much more widely. Last year more than 800,000 patients, mostly middle-aged men, were treated with testosterone. More studies are needed to determine the risks, such as prostate cancer and cardiovascular disease, associated with its use.
NTP Principles: not specified
Agents and Status
The following information relates to the specific agent and may include history from earlier or later nominations for this same agent.
Agent Name: Testosterone
Agent Name: Testosterone propionate
Agent Name: Testosterone oenanthate